New York, NY – As the global wellness industry shifts its focus from reactive treatment to proactive prevention, a breakthrough in nutritional science is garnering significant attention from health professionals and consumers alike. At the center of this movement is IMMUSE™, a pioneering postbiotic developed by Kyowa Hakko, designed to fortify the human immune system at its most fundamental level. Unlike traditional supplements that offer localized or temporary boosts, this novel ingredient—clinically known as Lactococcus lactis strain Plasma (LC-Plasma)—represents a paradigm shift in how we understand and support our natural defenses.

Main Facts: A New Class of Immune Support

In an era defined by high-stress lifestyles, environmental challenges, and a heightened awareness of respiratory health, the demand for scientifically validated immune support has never been higher. IMMUSE™ enters this landscape not as a vitamin or a mineral, but as a "postbiotic"—the latest evolution in the biotic family (prebiotics, probiotics, and postbiotics).

The primary distinction of IMMUSE™ lies in its unique mechanism of action. While most immune-supporting ingredients focus on stimulating specific "effector" cells, such as Natural Killer (NK) cells, IMMUSE™ targets the "commander-in-chief" of the immune system: the plasmacytoid dendritic cell (pDC). By activating these high-level regulatory cells, the ingredient triggers a comprehensive, system-wide immune response that coordinates various branches of the body’s natural defense network.

Developed by the Japanese biotechnology giant Kyowa Hakko, IMMUSE™ is a clean-label, non-GMO, and allergen-free ingredient. Its heat-treated nature makes it incredibly stable, allowing it to be integrated into a wide variety of delivery formats, from traditional capsules and tablets to contemporary gummies, powders, and functional beverages. This versatility, combined with a decade of rigorous clinical backing, has positioned it as a gold-standard ingredient in the global nutraceutical market.

Chronology: The Decades-Long Journey of LC-Plasma

The story of IMMUSE™ is not one of overnight success but of meticulous scientific inquiry spanning over thirty years. The timeline of its development reflects the broader evolution of immunology and microbiology.

The 1990s: The Discovery of the "Commander"

The scientific foundation was laid in the late 1990s when researchers first identified plasmacytoid dendritic cells (pDCs). Before this discovery, the scientific community understood that various white blood cells played roles in defense, but they had not yet identified the central "signaling hub" that coordinated these efforts. The identification of pDCs was a landmark moment, revealing a cell type capable of producing large quantities of Type I interferons—crucial signaling molecules that alert the entire immune system to a threat.

The Search for a Stimulant

Following the discovery of pDCs, the challenge shifted to nutrition: Could a dietary ingredient safely and effectively stimulate these cells? Researchers at Kirin Holdings (the parent company of Kyowa Hakko) embarked on a massive screening process. They tested more than 100 different strains of lactic acid bacteria (LAB), seeking one that could interact directly with pDCs.

The Breakthrough: Identifying LC-Plasma

After years of testing, Lactococcus lactis strain Plasma (LC-Plasma) emerged as the only strain capable of activating pDCs. Unlike other probiotics that passed through the digestive tract with localized benefits, LC-Plasma showed a unique ability to be recognized by the immune sensors in the small intestine, specifically the Peyer’s patches, which then signaled the pDCs.

Refinement and Commercialization (2010s–Present)

Once the strain was identified, the team developed a proprietary heat-treatment process. This transformed the live bacteria into a "postbiotic." This was a critical step; by using heat-killed cells, the researchers ensured the ingredient remained stable at room temperature and resistant to the harsh environment of food and beverage processing, without losing its immune-stimulating properties. In 2023, the ingredient gained significant traction in the North American market, winning awards for innovation and becoming a staple in high-end wellness formulations.

Supporting Data: The Science of pDC Activation

The efficacy of IMMUSE™ is supported by a robust portfolio of scientific literature, a rarity in the supplement industry where many products rely on "borrowed" science or general studies on vitamins.

Clinical Trial Overview

To date, IMMUSE™ is backed by more than 30 published studies, including 15 human clinical trials. These trials consist of 13 efficacy studies and two safety studies. This body of work is peer-reviewed and provides a high level of confidence for healthcare practitioners.

The Multi-Level Immune Response

The data reveals that once IMMUSE™ activates the pDC, a "cascade effect" occurs. The pDC releases signaling molecules that activate:

1. NK (Natural Killer) Cells: The first line of defense against virally infected cells.
2. Killer T-Cells: Cells that specifically target and destroy pathogens.
3. Helper T-Cells: Cells that coordinate the long-term immune response.
4. B-Cells: Responsible for antibody production.

Real-World Outcomes

In human trials, participants taking a daily dose of 50mg of IMMUSE™ (LC-Plasma) reported several significant benefits compared to placebo groups:

• Respiratory Health: A notable reduction in the duration and severity of seasonal respiratory challenges.
• Physical Performance: Athletes and high-intensity exercisers showed reduced fatigue and a faster return to baseline immune function following strenuous workouts.
• Work/School Attendance: Studies conducted in community settings showed fewer missed days of work or school among those supplemented with the postbiotic.

Official Responses: Insights from the Industry

To better understand the practical applications of this science, we spoke with Karen Todd, a Registered Dietitian and the Vice President of Global Brand Marketing at Kyowa Hakko USA. Todd has been a vocal advocate for evidence-based nutrition and sees IMMUSE™ as a vital tool for modern living.

"Life is measured in moments—both big and small," Todd explains. "Whether you’re hiking with friends, working toward a promotion, or spending quality time with your kids, you want to feel your best. But if your natural defenses are weakened by stress, fatigue, or lack of sleep, it’s hard to keep up."

Todd emphasizes that the "proactive" nature of IMMUSE™ is its greatest strength. "Most people wait until they feel a scratch in their throat to think about their immune system. IMMUSE™ is designed for daily, year-round support. It’s about keeping the ‘commander’ of your immune system alert so that the body is always prepared."

When asked about the versatility of the ingredient, Todd noted, "Because it is a heat-treated postbiotic, it is incredibly stable. This allows us to put it into gummies, tablets, or even functional waters. It’s clean, non-GMO, and vegetarian, which aligns with what today’s conscious consumer is looking for."

Implications: The Future of the Postbiotic Market

The rise of IMMUSE™ signals a broader shift in the $150 billion global supplement market. As consumers become more educated, they are moving away from "mega-doses" of single vitamins and toward complex, biotics-based solutions that work in harmony with the body’s existing biological pathways.

The Postbiotic Advantage

The success of IMMUSE™ highlights the inherent advantages of postbiotics over probiotics. While probiotics require live cultures to reach the gut—often necessitating refrigeration and careful handling—postbiotics are shelf-stable and have a much longer life cycle. This makes them more accessible and easier to integrate into daily life, which is essential for the "daily support" model Todd describes.

Impact on the Fitness Industry

The data regarding exercise-induced stress is particularly relevant for the fitness industry. It is a well-known phenomenon that high-intensity training can temporarily suppress the immune system (the "open window" theory). By supporting immune function at the cellular level, IMMUSE™ offers a new way for athletes to maintain their training volume without the downtime associated with overtraining or seasonal illness.

A New Standard for Transparency

Perhaps the most significant implication is the pressure this puts on other supplement manufacturers. By bringing 15 human clinical trials to the table, Kyowa Hakko is setting a high bar for what "science-backed" actually means. In a crowded marketplace, the transparency of the LC-Plasma research provides a blueprint for how nutritional ingredients can gain the trust of both the medical community and the general public.

As we look toward the future of preventative medicine, the focus is clearly shifting inside the cell. With its ability to bridge the gap between traditional nutrition and advanced biotechnology, IMMUSE™ stands as a testament to the power of targeted, cellular-level defense. For those living an active, modern lifestyle, the message is clear: the best defense is a well-coordinated offense, led by the commanders of the immune system.